繁體
简体中文
繁體中文

State Street多重資產實際報酬主動型ETF RLY 深 滬

等待開盤 11-19 09:30:00 美东时间

35.0901

-0.670

-1.87%

华盛通華盛通
立即下載
  • 最 高36.0632
  • 今 開35.205
  • 成交量 5.66万股
  • 最 低 35.08
  • 昨 收 35.76
  • 總市值 51.23万
  • 52周最高 38.38
  • 市盈率 靜 --
  • 換手率 387.81%
  • 52周最低 29.9872
  • 委 比 38.46%
  • 總股本 1.46万
  • 歷史最高 38.38
  • 量 比 0.62
  • 振 幅 2.75%
  • 歷史最低 6.2756
  • 每 手 1
  • 風險率 2.17%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

    <p>Relay Therapeutics, Inc. announced the appointment of Dr. Claire Mazumdar to its Board of Directors. Dr. Mazumdar brings extensive experience in clinical-stage oncology and drug development, particularly in precision medicine. She previously founded Bicara Therapeutics and led business development at Rheos Medicines, collaborating with Roche Pharmaceuticals. With her expertise, she will support Relay Therapeutics in advancing its drug discovery efforts.</p>

    2025-06-11 20:05

  • Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

    Relay Therapeutics reported promising interim data for RLY-2608, showing a median progression-free survival (PFS) of 10.3 months overall and 11.0 months for second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The data support the planned Phase 3 ReDiscover-2 study to begin mid-2025 and highlight RLY-2608's improved tolerability and efficacy compared to current treatments. Next-generation triplet combinations with atirmociclib and ribociclib are also being evaluated.

    2025-06-02 11:00